Immuneering (IMRX) Profit After Tax: 2020-2023
Historic Profit After Tax for Immuneering (IMRX) over the last 4 years, with Dec 2023 value amounting to -$15.1 million.
- Immuneering's Profit After Tax fell 13.88% to -$15.1 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$53.5 million, marking a year-over-year decrease of 5.86%. This contributed to the annual value of -$53.5 million for FY2023, which is 5.86% down from last year.
- Latest data reveals that Immuneering reported Profit After Tax of -$15.1 million as of Q4 2023, which was down 19.76% from -$12.6 million recorded in Q3 2023.
- In the past 5 years, Immuneering's Profit After Tax ranged from a high of -$3.2 million in Q2 2020 and a low of -$15.1 million during Q4 2023.
- Its 3-year average for Profit After Tax is -$11.5 million, with a median of -$12.4 million in 2023.
- Its Profit After Tax has fluctuated over the past 5 years, first plummeted by 149.56% in 2021, then rose by 1.94% in 2023.
- Quarterly analysis of 4 years shows Immuneering's Profit After Tax stood at -$5.8 million in 2020, then crashed by 84.79% to -$10.8 million in 2021, then decreased by 22.82% to -$13.2 million in 2022, then fell by 13.88% to -$15.1 million in 2023.
- Its last three reported values are -$15.1 million in Q4 2023, -$12.6 million for Q3 2023, and -$12.2 million during Q2 2023.